|   LifeSciVC

Our Year In Review: Annual Talk On Macro, Biotech, and Atlas

By Bruce Booth, DPhil, Partner

At the end of every year, we host both our Atlas Venture Annual Meeting for our fund investors (Limited Partners) and our Atlas Retreat for senior industry executives.  As a kickoff for these two meetings, we typically open with a “Year In Review” to frame up some of the important themes facing biopharma. This year, for the first (and maybe only) time, we’ve decided to share a video recording of the Year In Review 2018 here at LifeSciVC, with voiceover accompanying the slides.  Here it is:

View the talk.


  |   LifeSciVC

Biotech Insider Stock Sales: Peer Benchmarks And Guidelines

By Bruce Booth, DPhil, Partner

Over the past six years, the biotech sector has experienced an incredible run of IPOs, reflecting the longest and largest “open window” for new offerings. Much has been written about post-IPO performance here and elsewhere, but there’s been little discussion about equity sales by executive teams following these IPOs.

Read more.


  |   In the News

A Talk With Robert Jacks, New CEO of NASH and Fibrotic Drugmaker Indalo

Robert Jacks, co-founder and former chief financial officer of Symbiomix Therapeutics, has taken over the reins of Cambridge, Mass.-based Indalo Therapeutics and will help guide the company in the development of therapies for patients suffering from serious fibrotic diseases such as NASH and idiopathic pulmonary fibrosis (IPF).

Read more.


  |   From the Trenches

Predicting The Next Dominoes to Fall in 2019

Today I will continue my time-honored January tradition of an optimistic blog post providing some bold predictions for the year ahead.

This post was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

Leadership At All Levels In Biotech

Biotech is an industry that calls for leaders. It requires people who are willing to take risks, conquer new science, and have endurance for the many years it takes to develop a new medicine. In addition, professionals who thrive in biotech have the know-how, confidence and guts to tackle business goals that are covered in uncertainty and complexity. These are ‘hard core’ leadership traits, and they are highly valued in biotech companies at all levels of job responsibilities.

This blog was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC

Read more.